Research programme: oral film diarrhoea therapeutic - IntelGenxAlternative Names: INT0019; INT0019/2009
Latest Information Update: 23 Dec 2013
Price : $50
At a glance
- Originator IntelGenx Corp.
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Irritable bowel syndrome
Most Recent Events
- 12 Dec 2013 No development reported - Preclinical for Irritable bowel syndrome in Canada (PO)